User login
Community Oncology Editor-in-Chief Dr. David Henry spoke with Dr. Corey Langer at the Oncology Practice Summit in Las Vegas about which lung cancer patients are eligible for bevacizumab therapy, maintenance therapy, and the latest on erlotinib therapy for EGFR-mutated patients.
The Oncology Practice Summit was the 8th annual meeting of Community Oncology, the journal of clinical issues in community practice. Dr. Henry was a co-chair of the Summit, which was hosted this year by Community Oncology as well as The Journal of Supportive Oncology and The Oncology Report.
Community Oncology Editor-in-Chief Dr. David Henry spoke with Dr. Corey Langer at the Oncology Practice Summit in Las Vegas about which lung cancer patients are eligible for bevacizumab therapy, maintenance therapy, and the latest on erlotinib therapy for EGFR-mutated patients.
The Oncology Practice Summit was the 8th annual meeting of Community Oncology, the journal of clinical issues in community practice. Dr. Henry was a co-chair of the Summit, which was hosted this year by Community Oncology as well as The Journal of Supportive Oncology and The Oncology Report.
Community Oncology Editor-in-Chief Dr. David Henry spoke with Dr. Corey Langer at the Oncology Practice Summit in Las Vegas about which lung cancer patients are eligible for bevacizumab therapy, maintenance therapy, and the latest on erlotinib therapy for EGFR-mutated patients.
The Oncology Practice Summit was the 8th annual meeting of Community Oncology, the journal of clinical issues in community practice. Dr. Henry was a co-chair of the Summit, which was hosted this year by Community Oncology as well as The Journal of Supportive Oncology and The Oncology Report.